Comparing Botox Injection and Combined Mirabegron and Solifenacin Therapy for Women With Overactive Bladder Muscles

What this Trial Is About

This research aims to compare the effects of botulinum toxin type A bladder injections with combined drug therapy using Mirabegron and Solifenacin in patients with detrusor overactivity. The study focuses on patients who have not responded well to single-drug treatments, specifically anti-muscarinics or beta-3 adrenoceptor agonists, to better understand symptom relief and bladder function. Participants are divided into two groups one receiving intradetrusor onabotulinumtoxinA injections, which work by blocking nerve signals to reduce bladder muscle overactivity, and the other receiving a combination of Mirabegron and Solifenacin medications. Both treatments are evaluated over time to compare their impact on symptoms and bladder performance. Throughout the study, participants will have their urinary symptoms and quality of life assessed using questionnaires at multiple points before treatment and at 1 month, 3 months, 6 months, and 1 year after treatment. Objective bladder function measures, such as bladder capacity and pressure during involuntary contractions, will also be monitored between 3 months and 1 year. The trial uses a randomized, double-blind design to ensure reliable comparison between the two treatment approaches.

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity